Clindamycin and bacterial load reduction as prophylaxis for surgical site infection after below-knee flap and graft procedures: A trial protocol

Aust J Gen Pract. 2024 Nov;53(11):859-863. doi: 10.31128/AJGP-06-23-6881.

Abstract

Background and objectives: Management of skin cancer comprises a substantial proportion of general practitioner (GP) workload in Australia. Flap and graft procedures below the knee have an increased risk of infection. Antibiotic resistance is a threat to global health, and any decision about antibiotic prophylaxis must balance adverse outcomes of antibiotic use with patient morbidity. This study will investigate the effectiveness of two interventions to prevent surgical site infection (SSI) after below-knee surgery: (1) 450 mg of clindamycin preoperatively and postoperatively; and (2) preoperative chlorhexidine wash and nasal mupirocin.

Method: This prospective randomised controlled trial will be conducted across three skin cancer clinics over nine months, with 155 participants. Consecutive patients presenting for below-knee flap and graft procedures will be eligible to participate. The primary outcome is superficial SSI in the first 30 days following excision. Secondary outcomes include adverse effects (anaphylaxis, skin irritation and foreign body reaction) and patterns of antibiotic resistance.

Results: As this is a study protocol paper, there are no results available to present.

Discussion: As this is a study protocol paper, there are no results to be discussed.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Anti-Bacterial Agents* / therapeutic use
  • Antibiotic Prophylaxis / methods
  • Antibiotic Prophylaxis / statistics & numerical data
  • Australia
  • Bacterial Load / drug effects
  • Bacterial Load / methods
  • Chlorhexidine / therapeutic use
  • Clindamycin* / therapeutic use
  • Female
  • Humans
  • Male
  • Prospective Studies
  • Skin Neoplasms / surgery
  • Surgical Flaps* / adverse effects
  • Surgical Wound Infection* / prevention & control

Substances

  • Clindamycin
  • Anti-Bacterial Agents
  • Chlorhexidine